Related Experiment Videos
[Progressive muscular dystrophies and drug risks]
Therapie
|March 1, 1994
Summary
Therapeutic agents are vital for treating intercurrent diseases in progressive muscular dystrophy. However, some treatments can harm muscles, cause myopathy, or affect cardiac and respiratory functions, necessitating careful use or contraindication.
Area of Science:
- Neurology
- Pharmacology
- Genetics
Context:
- Progressive muscular dystrophy (PMD) management requires addressing intercurrent diseases.
- Therapeutic interventions for PMD patients carry potential risks.
Purpose:
- To review the potential adverse effects of therapeutic agents used in progressive muscular dystrophy.
- To highlight agents that may impair muscular, cardiac, or respiratory functions.
Summary:
- Certain medications can induce rhabdomyolysis, toxic myopathy, or inflammatory myopathy.
- Other treatments may lead to metabolic, functional, cardiac, or respiratory impairments.
- These adverse effects necessitate careful consideration and potential contraindication of specific therapies.
Impact:
- Informed clinical decision-making for progressive muscular dystrophy treatment.
- Improved patient safety by avoiding detrimental therapeutic agents.
- Enhanced understanding of drug-induced complications in neuromuscular disorders.